Integrate AI and Machine Learning to Leverage Medical Insights, Diagnostics Innovation for Improved Customer Engagement, Optimized Medical Affairs Function and Patient Outcomes

On-Demand Content | Virtual Event

AGENDA – ALL TIMES ARE IN EASTERN TIME

Come visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and the knowledge you’re looking to gain through our bespoke 1:1 match-making services.
Felipe Navarrera
Vice President Medical Affairs
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA)

Sanjay Singhvi
Director
VMLY&R HEALTH
  • The implementation of Artificial Intelligence (AI) in the nations’ healthcare ecosystem offers unique opportunities to improve health care delivery, its efficiency, and patient outcomes but has potentially significant challenges
  • As the technical sophistication of AI continues to evolve, many pharma companies will likely partner with- or acquire- external vendors to leverage AI tech to focus research efforts more efficiently and bring products to market more quickly, competitively, and effectively
  • Together, AI may ease administrative/ repetitive burdens, improve analysis of big data for improved decision making and ultimately improve “customer” service for the key stakeholders in HC
Alan Polnariev, PharmD, MS
National Clinical Account Director
Proudly serving the VA and DoD
US Payer Medical
ASTRAZENECA
Medical Insights generated from digital healthcare collected data have emerged as a promising approach to help accelerate drugs' early research and developments and advanced digital immunotherapy. In this session we will highlight challenging requirements to regulate Medical insights to support clinical claims:

  • Solve data governance and privacy using advanced deep learning to anonymize patients’ data (images, cough voice data...)
  • Quality fresh and regulated data is hard to obtain hence using a federated learning approach to leverage regional sensitive data is highly recommended.
  • Qualification and verification of medical devices used to collect data.
  • Identity management of patients and related used medical devices where data is collected.
  • Qualification of federated model-training pipeline to train qualified models.
  • Connection of partitioned data sets and model version.
Abdel Dridi
Global Head of Digital Health Technologies (DHT),
GENENTECH
  • Demonstration and walk-through of the outcomes of applying AI/ML/NLP techniques to insights captured from multiple sources
  • In practical, everyday terms, how can such outputs reduce cycle-time, increase efficiency, and improve your decision making?
  • What are the key requirements to consider when integrating the power of AI/ML into your daily insights workflow?
Sanjay Singhvi
Director
VMLY&R HEALTH
Interactive Discussions on Relevant Topics - Guided Conversations Prompted by Videos

  • Engage with fellow virtual participants
  • Discuss relevant topics, common challenges and best practices
  • Discover a new and fun way to connect with like-minded peers
This session will focus on:

  • Basic understanding of what is a medical device
  • Difference between SiMD and SaMD
  • QMS requirements for developing SaMD
  • Regulatory activities for Changes to SaMD
  • Validation requirements for SaMD development
Vivek Thakkar
Regulatory and Quality
AI-Based Software as Medical Device (SaMD)
IDOVEN
Rajesh Lal
Biostatistics and Data Science, Medical Affairs Senior Consultant
GENENTECH
Come visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and the knowledge you’re looking to gain through our bespoke 1:1 match-making services.
Prathamesh Karmalkar
Principal Data Scientist - Text Analytics, NL, NLU and Artificial Intelligence
MERCK GROUP

Ana Amaral
Insights and Analytics Lead – Chief Medical Officer (CMO) Organization
MERCK GROUP
The uniqueness of the Medical Information and Pharmacovigilance (MIPV) department is that It has rich data of unsolicited customer feedback and responses being kept in the validated medical inquiry database, which can be a great source for AI training and Big Data Analysis.  With HCPs and patients increased their preferences in obtaining information from inquiries to MI departments, the MI department has an invaluable database that can help Medical Affairs teams by:

  • Strengthen insights and deepen engagements with HCPs through more directed discussions using unsolicited feedback as key points for field team members.
  • Monitor various medical activities through inquiries coming in:
  • Learning event effectiveness (OLAs, CME)
  • Topics of Interests
  • Business Decisions
  • Ability to create compelling messages and clear calls to action through better insights and data visualization.
An AI tool: MIPV Data Uses For AI Semantic Sentence Analysis (MUFASA) was developed by myself, which leverages the novel techniques in AI and Big Data Analysis such as sentence transformers, clustering, and visualization. It allows MIPV department users to interactively perform searches, data analysis, and data visualization.

Karen Ng, PharmD
Medical Affairs and Medical Education Resident
LEO PHARMA
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speakers may have questions for you as well!

Prathamesh Karmalkar
Principal Data Scientist - Text Analytics, NL, NLU and Artificial Intelligence
MERCK GROUP

Ana Amaral
Insights and Analytics Lead – Chief Medical Officer (CMO) Organization
MERCK GROUP

Karen Ng, PharmD
Medical Affairs and Medical Education Resident
LEO PHARMA
  • Developing Big Data and real-world evidence to support drug development, including real-world evidence, in-house data and scientific analysis
  • Leveraging deep relationships with prescribers and opinion leaders and continually collecting feedback and signals from the market to provide critical input to drug development and life cycle management from early identification of promising compounds through post-launch market strategies
  • Using scientific data to cut through the marketing noise and profile its product fairly vs. the new entrant
Andrew Rosen
Medical Director, Field
MODERNA
  • Describe features of sentiment analysis systems
  • Understand the capabilities of Sentiment Analysis systems for the Medical Affairs Plan
  • Understand the current limitations of Sentiment Analysis Tools
  • Do´s and Don’ts when using Sentiment Analysis for Medical Affairs
Felipe Navarrera
Vice President Medical Affairs
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA)
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speakers may have questions for you as well!

Andrew Rosen
Medical Director, Field
MODERNA

Felipe Navarrera
Vice President Medical Affairs
ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA)
Medical affairs has more systems, tools, and data to them then ever before.  In fact, sometimes there is so much information that it can be overwhelming to keep up and process it all in real time and take action.  With this new knowledge medical affairs teams have ambition for omnichannel experiences for their external stakeholders and a desire for deeper collaboration internally.  However, many of these well intentioned efforts fall short because of the amount of time and effort they take to maintain and execute.

During this session Scott and Antonio are going to share the typical challenges that medical affairs leaders have building this integrated approach and how tools like a Next Best Action Engine brings the right information, to the right person, at the right time to be acted on.  Then, they will share examples of how Artificial Intelligence can supercharge the approach giving medical affairs insights that go beyond when can be identified through human analysis.

Scott Thompson
Co-CEO
ACCELERATION POINT

Antonio Pregueiro
VP New Offerings and Practice Lead
IQVIA